Translating Scientific Discoveries Into Medical Practice
NIAID has been at the forefront of cutting-edge biomedical research for decades. The work performed in its labs has furthered the understanding of the immune system and led to significant advances in the fields of immunology and infectious disease research.
But it’s a long path from basic scientific discoveries to approved vaccines, treatments, or diagnostic tools. NIAID is constantly pursuing collaborations with industry and academia to develop its technologies and materials into products that improve public health.
The NIAID Office of Technology Development (OTD) facilitates collaborative relationships between NIAID investigators and the broader scientific community.
Highlighted Licensing and Collaboration Opportunities
See the complete list of Recent Licensing and Collaboration Opportunities.
Recent Happenings
United States Patent 8,017,130 was issued on September 13, 2011, for a method of accelerated vaccination against Ebola virus. Lead inventors: Gary J. Nabel, M.D., Ph.D., Vaccine Research Center (VRC); Nancy Sullivan, Ph.D., VRC; Peter Jahrling, Ph.D., Emerging Viral Pathogens Section, Integrated Research Facility
United States patent US 7,993,919 was issued August 9, 2011, for a method of inducing memory B-cell development and terminal differentiation. Lead inventors: Herbert C. Morse III, M.D., Laboratory of Immunopathology
NIAID and Microbiotix signed a cooperative research and development agreement (CRADA) for Development of an antimalarial drug by targeting the plasmodial surface anion channel present in rodent, avian, and primate malaria species. NIAID principal investigator: Sanjay Desai, M.D., Ph.D., Laboratory of Malaria and Vector Research
NIAID and the University of Southern California signed a research collaboration agreement (RCA) to Design and construct replication defective lentiviral vecors expressing proteins from viruses of the filoviridae family and to evaluate their potential efficacy as preventative vaccines. NIAID principal investigator: Gary J. Nabel, M.D., Ph.D., Vaccine Research Center
See the complete list of Technology Development Recent Happenings.
